Tarsus Pharmaceuticals, Inc. SEC Filing
TARS submitted a Form 144 notice reporting an intended sale of 3,125 shares of Common Stock tied to restricted stock vesting on 03/16/2026, with a listed dollar amount of $216,920.94.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TARS submitted a Form 144 notice reporting an intended sale of 3,125 shares of Common Stock tied to restricted stock vesting on 03/16/2026, with a listed dollar amount of $216,920.94. The filing also records a prior sale of 8,366 shares on 03/04/2026 by Seshadri Neervannan with a listed dollar amount of $641,421.22. The broker listed is Fidelity Brokerage Services LLC (address shown) and the trading venue is NASDAQ.
Insights
Form 144 discloses a proposed disposition of 3,125 vested shares and a recent 8,366-share sale.
The filing lists 3,125 shares associated with restricted stock vesting on 03/16/2026 and a reported sale of 8,366 shares on 03/04/2026 by Seshadri Neervannan. Dollar figures ($216,920.94 and $641,421.22) are shown adjacent to those entries.
Cash‑flow treatment and whether sales will occur pursuant to a prearranged plan are not stated in the excerpt; subsequent regulatory filings or broker confirmations would show execution details and timing.
AI-generated analysis. How Rhea-AI works. Not financial advice.